Vertex Pharmaceuticals
VRTX
1,033 hedge funds and large institutions have $50.2B invested in Vertex Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 201 funds opening new positions, 336 increasing their positions, 368 reducing their positions, and 87 closing their positions.
131% more first-time investments, than exits
New positions opened: 201 | Existing positions closed: 87
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
23% more call options, than puts
Call options by funds: $673M | Put options by funds: $547M
20% more capital invested
Capital invested by funds: $41.8B → $50.2B (+$8.37B)
11% more funds holding
Funds holding: 933 → 1,033 (+100)
1.32% more ownership
Funds ownership: 89.26% → 90.57% (+1.3%)
9% less repeat investments, than reductions
Existing positions increased: 336 | Existing positions reduced: 368
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$820M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$267M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$201M |
| 4 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$180M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$374M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$203M |
| 3 |
Two Sigma Investments
New York
|
-$174M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$152M |
| 5 |
Two Sigma Advisers
New York
|
-$150M |
VRTX Hedge Fund Activity: Q4 2021 in Review
1,033 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2021, worth a combined $50.2B — up 20% from $41.8B a quarter earlier.
Buyers outnumbered sellers: 201 funds opened new VRTX positions and 87 closed out — a net gain of 114 holders — while 336 added to existing stakes and 368 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $820M. The largest seller was Capital International Investors, cutting an estimated $374M.
- 1,033 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2021, up from 933 in Q3 2021.
- Funds reported $50.2B of Vertex Pharmaceuticals stock for Q4 2021, up 20% quarter-over-quarter.
- 201 funds opened new Vertex Pharmaceuticals positions in Q4 2021 and 87 closed out, a net change of +114 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2021 was Fidelity Investments, an estimated $820M added.
- The largest Vertex Pharmaceuticals seller in Q4 2021 was Capital International Investors, an estimated $374M sold.
Based on aggregated 13F filings for Q4 2021.